NCT00532441View on ClinicalTrials.gov

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Erlotinib

Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28

DRUG

Docetaxel

Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15

Trial Locations (12)

19713

Helen F. Graham Cancer Center, Newark

46202

IN Onc/Hem Associates, Indianapolis

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47303

Medical Consultants, P.C., Muncie

47403

Cancer Care Center of Southern Indiana, Bloomington

60611

Northwestern University Feinberg School of Medicine, Chicago

60612

Rush-Presbyterian St. Luke's Medical Center, Chicago

63110

Siteman Cancer Center, St Louis

68114

Methodist Cancer Center, Omaha

Sponsors

Collaborators (2)

Sanofi
OSI Pharmaceuticals
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Gabi Chiorean, MD

OTHER